DCAF16 Conjugates for Complete Protein Inactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for targeted protein degradation often fail to fully inactivate proteins due to their multiple functional domains, and many E3 ligases show restricted substrate specificities, limiting the effectiveness of protein degradation therapies.
Innovation Solution
Development of compounds that induce DDB1- and CUL4-associated factor 16 (DCAF16)-mediated protein degradation by forming conjugates with synthetic ligands at specific cysteine residues, modulating substrate selectivity of the CUL4-RBX1-DDB1 complex (CRL4) and generating diverse DCAF16 conjugates to target specific proteins for degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current targeted protein degradation methods are used, then some protein degradation is achieved, but the proteins are not fully inactivated due to multiple functional domains
Solution Approach 1:
The patent employs the CUL4-RBX1-DDB1 complex (CRL4) as a universal degradation platform that can target multiple different substrates through interchangeable DCAF16 proteins. Each DCAF16 is engineered with specific cysteine residues that can be covalently bound to various synthetic ligands, allowing the same core complex to degrade diverse target proteins completely by addressing all their functional domains through unified ubiquitination signaling.
Solution Approach 2:
The patent modifies the substrate selectivity parameters of the CRL4 complex by changing the cysteine residue positions (58, 100, 103, 119, 173, 177, 178, or 179) on DCAF16 proteins. By varying these positional parameters and introducing covalent binding at these sites, the system achieves complete protein inactivation while maintaining the ability to target different substrates through parameter variation rather than structural redesign.
2Reliability
If E3 ligases with restricted substrate specificity are used, then substrate selectivity is maintained, but the effectiveness of protein degradation therapy is limited
Solution Approach 1:
The patent segments the E3 ligase system into modular components: the core CUL4-RBX1-DDB1 complex remains constant for reliability, while DCAF16 proteins are segmented as interchangeable adapters that can be engineered with different cysteine residue configurations. This segmentation allows each DCAF16 variant to be optimized for specific substrate types, and the modular nature enables rapid assembly of new degradation targets, thereby improving overall therapeutic effectiveness without sacrificing selectivity.
Solution Approach 2:
The patent introduces DCAF16 proteins as intermediary components between the core CRL4 complex and target substrates. These intermediaries contain specific cysteine residues that serve as docking sites for synthetic ligands, which in turn bind to target proteins. This intermediary layer maintains the substrate selectivity of the core complex while expanding the range of degradable proteins through diverse ligand-DCAF16-target combinations, thus resolving the contradiction between selectivity and effectiveness.
3Productivity
If diverse DCAF16 conjugates are generated to target specific proteins, then degradation effectiveness is improved, but the complexity of the system increases
Solution Approach 1:
The patent creates a universal DCAF16 platform where a single core structure with defined cysteine residues can be covalently bound to multiple different synthetic ligands. This universal DCAF16 scaffold serves multiple functions: maintaining complex assembly, providing structural stability, and enabling diverse substrate targeting through ligand variation. By keeping the DCAF16 core universal and only varying the ligand portions, the system achieves diverse conjugate generation without proportionally increasing overall system complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The approach allows for efficient and selective degradation of target proteins, overcoming the limitations of existing methods by leveraging the CUL4-RBX1-DDB1 complex's substrate specificity and achieving complete protein inactivation with potential applications in therapeutic protein modulation.
Implementation Method 1
a DCAF16 protein covalently bound to a synthetic ligand at a cysteine residue
Implementation Method 2
the process is initiated via tagging of an ubiquitin... a majority of cellular proteins are degraded by the proteasome pathway
Data Source
AI summary
Disclosed herein are methods and compounds for inducing DDB1- and CUL4-associated factor 16 (DCAF16)-mediated protein degradation in mammalian cells. In some embodiments, also disclosed herein are methods of modulating the substrate selectivity of a DCAF16-CUL4-RBX1-DDB1 complex (CRL4) for modulating protein degradation.